Pharmacoutilization and costs of osteoarthritis: Changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice

Rheumatology

Volumn 42, Issue 7, 2003, Pages 879-887

  Russo, Pierluigi ^a   Capone, A ^b   Attanasio, E ^a   Baio, G ^c   Di Martino, M ^d   Degli Esposti, L ^d   Marchetta, F ^e   Buda, S ^d   Degli Esposti, E ^f   Caprino, L ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Outcomes Research Eng Consulting   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d Economics and Outcomes Research   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Local Health Unit   (Italy)

Author keywords

Clinical practice; Costs; COX 2 specific inhibitors; NSAIDs; Osteoarthritis

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST UTILITY ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HOSPITAL COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; ECONOMICS; FACTUAL DATABASE; HOSPITALIZATION; ITALY; MIDDLE AGED; NATIONAL HEALTH SERVICE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DATABASES, FACTUAL; DRUG COSTS; FEMALE; HOSPITALIZATION; HUMANS; ITALY; LACTONES; MALE; MIDDLE AGED; OSTEOARTHRITIS; PHYSICIAN'S PRACTICE PATTERNS; STATE MEDICINE; SULFONES;

EID: 0037685538     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg242     Document Type: Article

References (37)

1. Olshansky SJ, Cassel CK. Implications of the accrual of chronic nonfatal conditions in very elderly persons. In: Hamerman D, ed. Osteoarthritis. Public health implications for an aging population. London: John Hopkins University Press Baltimore, 1997:15-22.
2. Hochberg MC, Kasper J, Williamson J, Skinner A, Fried LP. The contribution of osteoarthritis to disability: preliminary data from the Women's Health and Aging Study. J Rheumatol 1995;431(Suppl.):16-8.
3. Yelin EH. Musculoskeletal conditions and employment. Arthritis Care Res 1995;8:311-7.
4. Pincus T, Mitchell JM, Burkhauser RV. Substantial work disability and earnings losses in individuals less than age 65 with osteoarthritis: comparison with rheumatoid arthritis. J Clin Epidemiol 1989;42:449-57.
5. Marsico A. Malattie reumatiche: impatto nel mondo del lavoro del 2000. Atti del III Congresso Nazionale del Collegio dei Reumatologi Ospedalieri - Terme di Telese (BN) 9-11 dicembre 1999;73-8.
6. Ciocci A. L'assistenza reumatologica alle soglie del terzo millennio - Introduzione. Riv It Biol Med 1998; 18(Suppl. 2):15-6.
7. Leardini G. Dimensioni e costi degli effetti indesiderati FANS-indotti nel paziente affetto da artrosi in Italia. Reumatismo 2000;52:223-33.
8. Istituto Nazionale di Statistica. Le condizioni di salute degli Italiani. Anno 1999. Roma: ISTAT, 2000.
9. Badley EM, Crotty M. An international comparison in the estimated effect of the aging of the population on the major cause of disablement, musculoskeletal disorders. J Rheumatol 1995;22:1934-40.
10. Langman MJ. Epidemiologic evidence on the association between peptic ulceration and anti-inflammatory drug use. Gastroenterology 1989;96:640-6.
11. Langman MJ, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
12. Langman M, Kahler KH, Kong SX, Finch E, Bentkover J. Use of gastroprotective agents and other healthcare resources among patients on nonsteroidal anti-inflammatory drugs in the United Kingdom [abstract]. 14th EULAR Congress. Glasgow, Scotland, June 6-11, 1999. Ann Rheum Dis 1999;58(Suppl. 1):202.
13. Lanas A. Impacto economico de los efectos secundarios gastrointestinales asociados a antiinflamatorios no esteroideos en el Servicio Nacional de Salud. Med Clin (Barcelona) 2000;114(Suppl. 3):46-53.
14. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:1163-9.
15. Laine L, Harper S, Simon T et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
16. Simon LS, Lanza FL, Lipsky PE et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. J Am Med Assoc 1999;282:1921-8.
17. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. J Am Med Assoc 2000;284:1247-55.
18. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
19. Watson DJ, Harper S, Zhao P et al. Treatment with rofecoxib required less gastrointestinal (GI) co-medication and fewer GI procedures than nonspecific cyclooxygenase inhibitors (NSAIDs). Proceedings of the American College of Rheumatology. Arthritis Rheum 1999;42:S403.
20. Russo P, Attanasio E, Baio G et al. Una prima valutazione economica dell'impiego di rofecoxib vs FANS convenzionali nell'artrosi. PharmacoEconomics Italian Research Articles 2001;3:81-9.
21. Hosmer D, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
22. Henry D, Lim LL, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996;312:1563-6.
23. Garcia Rodriguez L, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998;158:33-9.
24. Degli Esposti E, Berto P, Buda S, Di Nardo AM, Sturani A. The Pandora project: Results of the pilot study. Am J Hypertens 1999;12:790-6.
25. Degli Esposti E, Sturani A, Degli Esposti L et al. Pharmacoutilization of antihypertensive drugs: a model of analysis. Int J Clin Pharmacol Ther 2001;39:251-8.
26. Degli Esposti E, Ruffo P, Buda S, Valpiani G. Cardiovascular risk in hypertensive patients: results of the Pandora project. J Nephrol 2002;15:29-35.
27. Degli Esposti E, Sturani A, Di Martino M et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002;16:439-44.
28. Langman MJ, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated. Lancet 1994;343:1075-8.
29. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly person. Am J Epidemiol 1995;141:539-45.
30. Perez-Guttham S, Garcia Rodriguez L, Raiford D. Individual nonsteroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8:18-24.
31. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
32. Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338:719-26.
33. Hawky CJ, Karrasch JA, Szczepanski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338:727-34.
34. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99.
35. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26(Suppl. 56):18-24.
36. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105 (1B):31S-38S.
37. Wynne HA, Campbell M. Pharmacoeconomics of non-steroidal anti-inflammatory drugs (NSAIDs). Pharmacoeconomics 1993;3:107-23.